A phase 2 study of first line low dose afatinib in advanced non-small-cell lung cancer patients with mutated epidermal growth factor receptor
Phase 2
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000016444
- Lead Sponsor
- Kyoto Thoracic Oncology Research Group (KTORG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Not provided
Exclusion Criteria
1)obvious interstitial pneumonia or pulmonary fibrosis by chest CT 2)uncontrolled pleural or pericardial effusion 3)symptomatic brain metastasis 4)active multiple tumor 5)cannot take orally 6)obvious liver cirrhosis 7)clinically significant heart disease 8)infection which requires treatment 9)pregnancy 10)history of severe allergic reaction 11)anticontraceptive 12)inadequate patients whom physicians considered
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method Overall survival Safety Response rate